Cardeon (CARDEO) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
5 Jun, 2025Executive summary
Net sales for Q1 2025 increased to 1,591 KSEK from 1,345 KSEK year-over-year, mainly from consulting services to portfolio companies.
Operating loss improved to -1,724 KSEK from -2,573 KSEK compared to the same quarter last year.
Cash flow for the period was -99 KSEK, a significant improvement from -3,620 KSEK year-over-year.
Liquid assets at quarter-end were 109 KSEK, down from 4,099 KSEK at the end of Q1 2024.
Portfolio value at fair value was 54.5 MSEK, with a net asset value of 56.8 MSEK at quarter-end.
Financial highlights
Net sales: 1,591 KSEK (Q1 2024: 1,345 KSEK).
Operating income: -1,724 KSEK (Q1 2024: -2,573 KSEK).
Result after financial items: -1,533 KSEK (Q1 2024: -2,876 KSEK).
Cash flow from operations: -1,361 KSEK (Q1 2024: -2,764 KSEK).
Equity at quarter-end: 54,314 KSEK (Q1 2024: 108,676 KSEK).
Outlook and guidance
Management remains confident in long-term growth due to demographic trends and increased demand for medtech and life science solutions.
Continued focus on building a portfolio of innovative companies with high growth potential in both listed and unlisted segments.
Ongoing efforts to strengthen the unlisted portfolio for long-term value creation through active ownership and strategic support.
Latest events from Cardeon
- Portfolio value fell 23% in Q4, but liquidity and clinical project progress remain solid.CARDEO
Q4 202525 Feb 2026 - Improved operating results and clinical progress drive a positive Q3, with strong equity ratio.CARDEO
Q3 202520 Nov 2025 - Improved results and clinical progress offset by a sharp drop in listed portfolio value.CARDEO
Q2 202528 Aug 2025 - Operating results improved and debt eliminated, but listed portfolio fell 15.7% in Q3.CARDEO
Q3 202413 Jun 2025 - Narrowed losses, portfolio shifts, and new capital define Cardeon's H1 2024.CARDEO
Q2 202413 Jun 2025 - Improved results and strategic milestones achieved, despite portfolio value decline.CARDEO
Q4 20246 Jun 2025